Biocon has launched its new Comprehensive Care division, dedicated to provide affordable solutions to critical illnesses like nosocomial infections, post surgical complications, trauma and medical emergencies. This would be the fifth division for Biocon, complementing the existing product portfolios in diabetology, oncology, nephrology and cardiology divisions.

Kiran Mazumdar Shaw, chairman and managing director, said, “There is a perceptible increase in hospital acquired infections with respect to critical care illnesses in India. This often requires treatment with specialized anti-infectives. Biocon's Comprehensive Care division has been set up to counter this growing challenge by providing affordable and specialized solutions to such patients.”

With the motto of 'improving life', Biocon's Comprehensive Care division will further extend the reach of Biocon's existing branded formulations to the critical care area. The division is introducing five new products in the initial phase of launch for the treatment of critical illnesses. These products will include platforms based on Pneumocandins (a class of Echinocandins), Lipopeptidies, specialised Cephalosporins and Carbapenams.